Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro

British Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2009, Pages 172-179

  Fanoe, Søren ^a,b   Jensen, Gorm Boje ^b   Sjøgren, Per ^c   Korsgaard, Mads P G ^d   Grunnet, Morten ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ECG; HERG and arrhythmia; Long QT

Indexed keywords

METHADONE; MORPHINE; OPIATE; OXYCODONE; POTASSIUM CHANNEL HERG; TRAMADOL;

ADULT; ANALGESIA; ARTICLE; BINDING AFFINITY; CARDIOTOXICITY; CELL STRAIN HEK293; CHRONIC PAIN; DENMARK; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEART REPOLARIZATION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; OOCYTE; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT INTERVAL; QT PROLONGATION; SIDE EFFECT; TORSADE DES POINTES; XENOPUS LAEVIS;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CROSS-SECTIONAL STUDIES; DENMARK; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PAIN; PATCH-CLAMP TECHNIQUES; PHARMACEUTICAL PREPARATIONS; TORSADES DE POINTES; YOUNG ADULT;

EID: 61349100039     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03327.x     Document Type: Article

References (31)

1. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002 137 : 501 4.
2. Hassan J, Bent-Hansen L, Jensen G. Livstruende, repetitiv arytmi hos patienter i højdosis methadonbehandling: Torsade de Pointes. Ugeskr Laeger 2004 166 : 3104 5.
3. Justo D, Gal-Oz A, Paran Y, Goldin Y, Zeltser D. Methadone-associated torsades de pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction 2006 101 : 1333 8.
4. Martell BA, Ray B, Gourevitch MN. The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med 2003 139 : 154 5.
5. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, Valerie P, Musset T, Gaspoz JM, Arnaud P, Dayer P, Desmeules J. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006 166 : 1280 7.
6. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007 93 : 1051 5.
7. Katchman AN, Mcgroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN. Influence of opioid agonists on cardiac human Ether-a-go-go related Gene K Currents. J Pharmacol Exp Ther 2002 303 : 688 94.
8. D'Aunno T, Pollack HA. Changes in methadone treatment practices: results from a national panel study, 1988-2000. JAMA 2002 288 : 850 6.
9. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006 125 : 172 9.
10. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006 31 : 506 11.
11. Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P. When 'enough' is not enough: new perspectives on optimal methadone maintenance dose. Mount Sinai J Med 2000 67 : 404 11.
12. Eriksen J, Jensen MK, Sjogren P, Ekholm O, Rasmussen NK. Epidemiology of chronic non-malignant pain in Denmark. Pain 2003 106 : 221 8.
13. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001 22 : 672 87.
14. Laguna P, Thakor NV, Caminal P, Jane R, Yoon H-R. New algorithm for QT interval analysis in 24-hour Holter ECG: performance and applications. Med Biol Eng Comput 1990 28 : 67 73.
15. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is 'normal'. J Cardiovasc Electrophysiol 2006 17 : 333 6.
16. Franz MR, Swerdlow CD, Liem L, Schaefer J. Cycle length dependence of human action potential duration in vivo. Effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies. J Clin Invest 1988 82 : 972 9.
17. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920 7 : 353 70.
18. Fridericia L. Die systolendauer im Elektrokardiogramm bei normalen Menschen und bei herzkranken. Acta Med Scand 1920 53 : 469 86.
19. Jespersen T, Grunnet M, Angelo K, Klærke D, Olesen S-P. Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes. Biotechniques 2002 32 : 536 40.
20. 2+-activated K+ channels. Pflugers Arch 2001 441 : 544 50.
21. Willumsen N. Increased throughput in ion channel drug development and exploration by automation of electrophysiology. Am Biotechnol Lab 2006 24 : 20 1.
22. Mathes C. QPatch: the past, present and future of automated patch clamp. Expert Opin Ther Targets 2006 10 : 319 27.
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986 327 : 307 10.
24. World Medical Association. World Medical Association Declaration of Helsinki. Cardiovasc Res 1997 35 : 2 3.
25. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keete DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL. QTc interval prolongation associated with intravenous methadone. Pain 2003 105 : 499 506.
26. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005 2 : 758 72.
27. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 350 : 1013 22.
28. Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 2005 26 : 119 24.
29. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang L, Sullivan AT, Wallis R. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003 58 : 32 45.
30. Cone EJ, Fant RV, Rohnay JM, Caplan YH, Ballina M, Reder RF, Haddox JD. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol 2004 28 : 217 25.
31. Jung BF, Reidenberg MM. Interpretation of opioid levels: comparison of levels during chronic pain therapy to levels from forensic autopsies. Clin Pharmacol Ther 2005 77 : 324 34.